Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Diethylamine Salicylate→

Diethylamine Salicylate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
4419-92-5
Molecular formula
C11H17NO3
Molecular weight
211.26 g/mol
Drug class
Topical salicylate derivativecounterirritant and local analgesic ingredient
Mechanism of action
Provides local salicylate-related anti-inflammatory and counterirritant effects following topical application. The clinical effect and pharmacokinetics depend on the formulation and co-ingredients.
Indications / reported uses
  • Topical symptomatic relief of localised muscle and joint pain in authorised external-use preparations; do not extrapolate to systemic salicylate indications

Sources: NLM MeSH — Diethylamine salicylate · PubMed — Diethylamine salicylate topical analgesic · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Diethylamine Salicylate Environmental Risk Assessment (ERA) (the Diethylamine Salicylate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.